Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunization Schedule | 10 | 2021 | 70 | 1.130 |
Why?
|
| Pneumococcal Vaccines | 8 | 2024 | 252 | 1.070 |
Why?
|
| Immunogenicity, Vaccine | 10 | 2022 | 91 | 0.930 |
Why?
|
| Haemophilus Vaccines | 3 | 2020 | 38 | 0.860 |
Why?
|
| Antibodies, Bacterial | 10 | 2024 | 149 | 0.820 |
Why?
|
| Antibodies, Viral | 12 | 2024 | 266 | 0.740 |
Why?
|
| HIV Infections | 13 | 2023 | 4946 | 0.700 |
Why?
|
| Vaccination | 10 | 2024 | 347 | 0.690 |
Why?
|
| Infant | 22 | 2024 | 2145 | 0.680 |
Why?
|
| Pneumococcal Infections | 7 | 2020 | 287 | 0.630 |
Why?
|
| Rotavirus Vaccines | 4 | 2021 | 53 | 0.590 |
Why?
|
| Vaccines | 3 | 2023 | 84 | 0.570 |
Why?
|
| Humans | 34 | 2024 | 14077 | 0.540 |
Why?
|
| South Africa | 24 | 2024 | 7312 | 0.520 |
Why?
|
| Immunization, Secondary | 6 | 2024 | 62 | 0.510 |
Why?
|
| Vaccines, Conjugate | 6 | 2024 | 161 | 0.430 |
Why?
|
| Antibodies, Neutralizing | 7 | 2023 | 285 | 0.410 |
Why?
|
| Immunoglobulin G | 10 | 2024 | 220 | 0.400 |
Why?
|
| Measles Vaccine | 2 | 2024 | 34 | 0.390 |
Why?
|
| Rotavirus | 3 | 2021 | 29 | 0.380 |
Why?
|
| Streptococcus agalactiae | 4 | 2017 | 197 | 0.380 |
Why?
|
| Vaccines, Combined | 3 | 2020 | 34 | 0.360 |
Why?
|
| Adult | 14 | 2023 | 5664 | 0.350 |
Why?
|
| Immunity, Maternally-Acquired | 4 | 2020 | 40 | 0.340 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 3 | 2020 | 28 | 0.320 |
Why?
|
| Double-Blind Method | 8 | 2022 | 263 | 0.320 |
Why?
|
| Streptococcus pneumoniae | 3 | 2023 | 320 | 0.300 |
Why?
|
| Chickenpox Vaccine | 2 | 2020 | 6 | 0.280 |
Why?
|
| Carrier State | 2 | 2020 | 89 | 0.270 |
Why?
|
| Female | 17 | 2024 | 8751 | 0.250 |
Why?
|
| Streptococcal Infections | 3 | 2016 | 179 | 0.240 |
Why?
|
| Nasopharynx | 3 | 2020 | 148 | 0.240 |
Why?
|
| Male | 13 | 2024 | 6489 | 0.230 |
Why?
|
| Nutritional Status | 1 | 2024 | 75 | 0.220 |
Why?
|
| Child | 4 | 2023 | 2180 | 0.220 |
Why?
|
| Child, Preschool | 7 | 2023 | 1675 | 0.210 |
Why?
|
| Haemophilus influenzae | 2 | 2020 | 42 | 0.210 |
Why?
|
| Vaccines, Subunit | 2 | 2020 | 8 | 0.210 |
Why?
|
| Poliovirus Vaccine, Inactivated | 2 | 2020 | 17 | 0.210 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2020 | 11 | 0.210 |
Why?
|
| Hepatitis B Vaccines | 2 | 2020 | 38 | 0.210 |
Why?
|
| Lymphadenopathy | 1 | 2022 | 4 | 0.200 |
Why?
|
| Prospective Studies | 6 | 2024 | 1131 | 0.200 |
Why?
|
| Antibody Formation | 3 | 2021 | 61 | 0.200 |
Why?
|
| Vaccines, Virus-Like Particle | 1 | 2021 | 2 | 0.190 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2023 | 137 | 0.190 |
Why?
|
| Pregnancy | 4 | 2020 | 1815 | 0.180 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2020 | 42 | 0.180 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2023 | 176 | 0.180 |
Why?
|
| Isoantibodies | 1 | 2020 | 15 | 0.180 |
Why?
|
| Hepatitis A Vaccines | 1 | 2020 | 2 | 0.180 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 251 | 0.170 |
Why?
|
| Autoantibodies | 1 | 2020 | 47 | 0.170 |
Why?
|
| HIV Seronegativity | 1 | 2020 | 52 | 0.170 |
Why?
|
| HLA Antigens | 1 | 2020 | 50 | 0.170 |
Why?
|
| Bacterial Proteins | 2 | 2017 | 117 | 0.170 |
Why?
|
| Maternal Exposure | 1 | 2019 | 14 | 0.170 |
Why?
|
| Measles | 1 | 2019 | 36 | 0.160 |
Why?
|
| Streptococcal Vaccines | 2 | 2016 | 45 | 0.160 |
Why?
|
| Young Adult | 6 | 2021 | 2357 | 0.150 |
Why?
|
| Adolescent | 6 | 2022 | 2858 | 0.150 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 6 | 0.140 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2017 | 15 | 0.140 |
Why?
|
| Tuberculosis | 1 | 2022 | 530 | 0.140 |
Why?
|
| Nervous System Diseases | 1 | 2015 | 12 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2020 | 867 | 0.120 |
Why?
|
| Middle Aged | 5 | 2021 | 3425 | 0.120 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2015 | 73 | 0.120 |
Why?
|
| Infant, Newborn | 4 | 2022 | 1410 | 0.120 |
Why?
|
| Immunoglobulin A | 3 | 2023 | 39 | 0.120 |
Why?
|
| Milk, Human | 1 | 2014 | 22 | 0.110 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2013 | 5 | 0.110 |
Why?
|
| Tetanus Toxoid | 1 | 2013 | 10 | 0.110 |
Why?
|
| Rotavirus Infections | 1 | 2014 | 46 | 0.110 |
Why?
|
| Breast Feeding | 1 | 2014 | 119 | 0.110 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 59 | 0.100 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2011 | 31 | 0.090 |
Why?
|
| Influenza B virus | 1 | 2011 | 42 | 0.090 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 54 | 0.090 |
Why?
|
| Influenza Vaccines | 1 | 2011 | 132 | 0.080 |
Why?
|
| Single-Blind Method | 2 | 2020 | 17 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 34 | 0.080 |
Why?
|
| Immunization | 2 | 2020 | 63 | 0.070 |
Why?
|
| Vaccines, Attenuated | 2 | 2020 | 27 | 0.070 |
Why?
|
| Influenza, Human | 1 | 2011 | 360 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 150 | 0.070 |
Why?
|
| Aged | 2 | 2021 | 1650 | 0.070 |
Why?
|
| Placebos | 2 | 2017 | 44 | 0.060 |
Why?
|
| Ghrelin | 1 | 2024 | 2 | 0.060 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2024 | 3 | 0.060 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 33 | 0.060 |
Why?
|
| Leptin | 1 | 2024 | 26 | 0.060 |
Why?
|
| Receptors, Fc | 1 | 2023 | 10 | 0.050 |
Why?
|
| Oxygen | 1 | 2023 | 25 | 0.050 |
Why?
|
| Antibodies, Blocking | 1 | 2023 | 9 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 60 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2022 | 42 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2023 | 84 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2022 | 39 | 0.050 |
Why?
|
| BCG Vaccine | 1 | 2022 | 20 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 43 | 0.050 |
Why?
|
| Australia | 1 | 2021 | 46 | 0.050 |
Why?
|
| Cross Reactions | 1 | 2021 | 44 | 0.050 |
Why?
|
| Safety | 1 | 2021 | 34 | 0.050 |
Why?
|
| Vaccine Potency | 1 | 2021 | 16 | 0.050 |
Why?
|
| Brazil | 1 | 2020 | 43 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2021 | 39 | 0.050 |
Why?
|
| United Kingdom | 1 | 2020 | 32 | 0.050 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 29 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2021 | 175 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2020 | 43 | 0.040 |
Why?
|
| Pandemics | 1 | 2023 | 280 | 0.040 |
Why?
|
| Placental Circulation | 1 | 2020 | 6 | 0.040 |
Why?
|
| Hospitalization | 1 | 2023 | 392 | 0.040 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2020 | 18 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2020 | 22 | 0.040 |
Why?
|
| Herpesvirus 3, Human | 1 | 2020 | 3 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 237 | 0.040 |
Why?
|
| Mutation | 1 | 2021 | 299 | 0.040 |
Why?
|
| Epitopes | 1 | 2020 | 97 | 0.040 |
Why?
|
| United States | 1 | 2020 | 129 | 0.040 |
Why?
|
| Risk Factors | 2 | 2015 | 1431 | 0.040 |
Why?
|
| Kinetics | 1 | 2017 | 65 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2017 | 45 | 0.040 |
Why?
|
| Immunoglobulin D | 1 | 2017 | 4 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 1149 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2017 | 13 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2017 | 23 | 0.030 |
Why?
|
| Mothers | 1 | 2017 | 190 | 0.030 |
Why?
|
| Africa | 1 | 2016 | 360 | 0.030 |
Why?
|
| Immunogenetic Phenomena | 1 | 2014 | 7 | 0.030 |
Why?
|
| Gastroenteritis | 1 | 2014 | 22 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 113 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 654 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 464 | 0.030 |
Why?
|
| Child Day Care Centers | 1 | 2013 | 4 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 45 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 325 | 0.030 |
Why?
|
| Incidence | 1 | 2015 | 655 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2013 | 133 | 0.030 |
Why?
|
| Age Factors | 1 | 2013 | 364 | 0.030 |
Why?
|
| HIV | 1 | 2015 | 380 | 0.030 |
Why?
|
| Time Factors | 1 | 2013 | 503 | 0.020 |
Why?
|
| Virus Cultivation | 1 | 2011 | 9 | 0.020 |
Why?
|
| Oropharynx | 1 | 2011 | 17 | 0.020 |
Why?
|
| Vaccines, Inactivated | 1 | 2011 | 23 | 0.020 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2011 | 23 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 77 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2013 | 767 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2011 | 303 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2011 | 468 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2011 | 1275 | 0.010 |
Why?
|